Behaviour Under Control: the Malign Misuse of Neuroscience

  • Alexander Kelle
  • Kathryn Nixdorff
  • Malcolm Dando
Chapter
Part of the Global Issues Series book series (GLOISS)

Abstract

Only in the last few centuries has the link between the brain and behaviour become clear, and only at the end of the nineteenth century was it demonstrated that the nervous system was made up of billions of separate nerve cells or neurons. We now know that during evolution complex networks of such neurons have developed in order to effect certain behaviours. Whilst the neurons of the central, peripheral and autonomic nervous systems vary enormously in form and function, they can be classed into three broad groups: sensory neurons which convey information into the central nervous system; effector neurons which carry information out of the central nervous system to muscles and other effector organs; and interneurons within the central nervous system which link the sensory and effector neurons and also have links with one another.

Keywords

Locus Coeruleus Excessive Daytime Sleepiness Memory Consolidation Nerve Agent Paradoxical Sleep 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes and References

  1. 1.
    SIPRI, The Problem of Chemical and Biological Warfare, Volume II of CB Weapons Today (Stockholm: Almqvist and Wiksell, 1973), pp.288–308 on novel chemical agents.Google Scholar
  2. 2.
    M. R. Dando, ‘Scientific and technological change and the future of the CWC: The problem of non-lethal weapons’, Disarmament Forum, 4, 2002, 33–44.Google Scholar
  3. 3.
    M. R. Dando, The Danger to the Chemical Weapons Convention from Incapacitating Chemicals, CWC Review Conference Paper No. 4, Department of Peace Studies, University of Bradford, 2003, available at: http://www.brad.ac.uk/acad/scwc.
  4. 4.
    H. Kitano, ‘Systems biology: a brief overview’, Introduction to a special section on systems biology: the Genome, Ligome and Beyond, Science, 295, 2002, 1662–4.CrossRefGoogle Scholar
  5. 5.
    E. J. Davidov, et al., ‘Advancing drug discovery through systems biology’, Drug Discovery Today, 8 (4), 2003, 175–83.CrossRefGoogle Scholar
  6. 6.
    C. M. Henry, ‘Systems biology: Integrative approach to drug discovery’, Chemical and Engineering News, 19 May 2003, 45–55.Google Scholar
  7. 7.
    L. Hood, ‘Leroy Hood expounds the principles, practice and future of systems biology’, Drug Discovery Today, 8 (10), 2003, 436–8.CrossRefGoogle Scholar
  8. 8.
    M. R. Dando, A New Form of Warfare: the Rise of Non-Lethal Weapons (London: Brassey’s, 1996), especially pp.136–68 (chapter 8, ‘An Assault on the Brain’).Google Scholar
  9. 9.
    J. M. Lakoski, et al., The Advantages and Limitations of Calmatives for Use as a Non-Lethal Technique, Applied Research Laboratory, College of Medicine, Pennsylvania State University, 2000.Google Scholar
  10. 10.
    A. Longstaff, Instant Notes: Neuroscience, 2nd edition (New York: Taylor and Francis, 2005).Google Scholar
  11. 11.
    Editorial, ‘New vistas for an old neurotransmitter’, Biological Psychiatry, 46 (9), 1999, 1121–3. (Introduction to a special issue covering pages 1121–320.)Google Scholar
  12. 12.
    G. Aston-Jones, et al., ‘Role of locus coeruleus in attention and behavioural flexibility’, Biological Psychiatry, 46 (9), 1999, 1309–20.CrossRefGoogle Scholar
  13. 13.
    B. Fernandez-Pastor, and J. J. Meana, ‘In vivo tonic modulation of the noradrenaline release in the rat cortex by locus coeruleus somatodendritic alpha2 adrenoceptors’, European Journal of Pharmacology, 442, 2002, 225–9.CrossRefGoogle Scholar
  14. 14.
    Edgewood RDEC, Scientific Conference in Chemical and Biological Defense Research: Abstract Digest, US Army Chemical and Biological Defense Command, Aberdeen Proving Ground, Maryland, 1989–94.Google Scholar
  15. 15.
    See Dando, A New Form of Warfare, note 8.Google Scholar
  16. 16.
    J. R. Docherty, ‘Subtypes of functional α1- and α2-adrenoceptors’, European Journal of Pharmacology, 361 (1), 1998, 1–15.CrossRefGoogle Scholar
  17. 17.
    M. M. Biicheler et al., ‘Two α2-adrenergic receptor subtypes, α2A and α2C, inhibit transmitter release in the brain of gene-targeted mice’, Neuroscience, 109 (4), 2002, 819–26.CrossRefGoogle Scholar
  18. 18.
    K. M. Small et al. ‘Pharmacology and physiology of human adrenergic receptor polymorphisms’, Annu. Rev. Pharmacol. Toxicol, 43, 2003, 381–411.CrossRefGoogle Scholar
  19. 19.
    See Dando, The Danger to the Chemical Weapons Convention, note 3.Google Scholar
  20. 20.
    SIPRI, The Problem of Chemical and Biological Warfare, note 1.Google Scholar
  21. 21.
    A. Frances and M. B. First, Your Mental Health: a Layman’s Guide to the Psychiatrists’ Bible (New York: Scribner, 1998), especially pp.109–16 (chapter 5, ‘Exposure to Traumatic Events’).Google Scholar
  22. 22.
    Longstaff, Instant Notes: Neuroscience, note 10.Google Scholar
  23. 23.
    J. LeDoux, ‘The power of emotions’, in R. Conlon (ed.), States of Mind: New Discoveries About How Our Brains Make Us Who We Are (New York: John Wiley and Sons 1999), pp.123–50.Google Scholar
  24. 24.
    J. L. McGough et al., ‘Amygdala modulation of memory consolidation: Interaction with other brain systems’, Neurobiology of Learning and Memory, 78, 2002, 539–52.CrossRefGoogle Scholar
  25. 25.
    B. Ferry and J. L. McGough, ‘Role of amygdala norepinephrine in mediating stress hormone regulation of memory storage’ Acta Pharmacol. Sin., 21 (6), 2000, 481–93.Google Scholar
  26. 26.
    J. L. McGough and B. Roozendaal, ‘Role of adrenal stress hormones in forming lasting memories in the brain’, Current Opinion in Neurobiology, 12, 2002, 205–10.CrossRefGoogle Scholar
  27. 27.
    B. Ferry et al., ‘Basolateral amygdala noradrenergic influences on memory storage are mediated by an interaction between β- and α1-adrenoceptors’, Journal of Neuroscience, 19 (2), 1999, 5119–123.Google Scholar
  28. B. Roozendaal, ‘Glucocortcoids and the regulation of memory consolidation’, Psychoneuroendocrinology, 25, 2000, 213–18.CrossRefGoogle Scholar
  29. 28.
    E. Vermetten and J. D. Bremner, ‘Circuits and systems in stress: I Preclinical Studies’, Depression and Anxiety, 15, 2002, 126–47.CrossRefGoogle Scholar
  30. 29.
    R. Grossman et al., ‘Neuroimaging studied on post-traumatic stress disorder’, Psychiatr. Clin. N. America, 25, 2002, 317–40.CrossRefGoogle Scholar
  31. 30.
    S. M. Southwick et al., ‘Role of norepinephrine in the pathophysiology and treatment of post-tramumatic stress disorder’, Biological Psychiatry, 46 (9), 1999, 1192–204.CrossRefGoogle Scholar
  32. 31.
    E. Baard, ‘The guilt-free soldier: New science raises the spectre of a world without regret’, The Village Voice, 22–8 January 2003.Google Scholar
  33. 32.
    F. C. Conahan, Human Experimentation: an Overview on Cold War Era Programs, Testimony before the Legislative and National Security Subcommittee, Committee on Government Operations, House of Representatives, September 28th. GAO/T-NSIAD-94-266 (Washington, DC: General Accounting Office 1994).Google Scholar
  34. 33.
    SIPRI, The Problem of Chemical and Biological Warfare, pp.302–03.Google Scholar
  35. 34.
    US Army Intelligence Agency, Letter Report: Incapacitating Agents, European Communist Countries, AST-1620R-100-90, US Army Foreign Science and Technology Center, 16 July 1990.Google Scholar
  36. 35.
    J. S. Ketchum and F. R. Sidell, ‘Incapacitating Agents’, in F. R. Sidell, E. T. Takafuji and D. R. Franz (eds), Medical Aspects of Chemical and Biological Warfare (Washington, DC: Office of the Surgeon General, 1997), pp.287–306.Google Scholar
  37. 36.
    See M. R. Dando, The Danger of the Chemical Weapons Convention from Incapacitating Chemicals.Google Scholar
  38. 37.
    M. R. Dando, A New Form of Warfare: the Rise of Non-Lethal Weapons (London: Brassey’s, 1996), pp.136–68.Google Scholar
  39. 38.
    E. Kagan, ‘Bioregulators as instruments of terror’, Clinics in Laboratory Medicine, 21 (3), 2001, 607–18.Google Scholar
  40. 39.
    B. Knickerbocker, ‘Military looks to drugs for battle readiness: As combat flights get longer, pilot use of amphetamines grows, as do side effects’, The Christian Science Monitor, 9 August 2002.Google Scholar
  41. 40.
    D-J. Dyk and S. W. Lockley, ‘Functional genomics of sleep and circadian rhythm’, J. Appl. Physiol., 92, 2002, 852–62.CrossRefGoogle Scholar
  42. G. K. Wang and A. Sehgal, ‘Signalling components that drive circadian rhythms’, Current Opinion in Neurobiology, 12, 2002, 331–8.CrossRefGoogle Scholar
  43. R. N. Van Gelder et al., ‘Circadian rhythms: in the loop at last’, Science, 300, 2003, 152–3.Google Scholar
  44. 41.
    M. R. Dando, The New Biological Weapons: Threat, Proliferation and Control (Boulder, CO: Lynne Rienner, 2001), pp.103–16.Google Scholar
  45. 42.
    ‘Scope/Information’, Nature Reviews: Neuroscience, available at: http://www.nature.com/nrn/info/scope.html.
  46. 43.
    T. Ideker, T. Galitski and L. Hood, ‘A new approach to decoding life: Systems biology’, Ann. Rev. Genomics Hum. Genet., 2, 2001, 343–72.CrossRefGoogle Scholar
  47. 44.
    M. M. Francis, J. E. Mellem and A. Villu Mericq, ‘Bridging the gap between genes and behaviour: recent advances in the electophysiological analysis of neural function’, Caenorhabditis elegans. Trends in Neuroscience, 26 (2), 2003, 90–9.CrossRefGoogle Scholar
  48. 45.
    United Kingdom, Background Paper on New Scientific and Technological Developments. Fifth Review Conference of the States Parties to the Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological (Biological) and Toxin Weapons and on their Destruction. BWC/CONF.V/4/Add.1 (Geneva, 26 October 2001).Google Scholar
  49. 46.
    M. R. Dando, A New Form of Warfare: the Rise of Non-Lethal Weapons (London: Brassey’s, 1996), especially chapter 6, ‘The Human Nervous System’.Google Scholar
  50. 47.
    R. R. Lliñas, I of the Vortex: From Neurons to Self (Cambridge, MA: MIT Press, 2002).Google Scholar
  51. 48.
    M. W. Dubin, How the Brain Works (Oxford: Blackwell, 2002).Google Scholar
  52. 49.
    R R. Sidell, ‘Nerve Agents’, in R R. Sidell, E. T. Takafuji and D. R. Franz (eds), Medical Aspects of Chemical and Biological Warfare (Washington, DC: Office of the Surgeon General, US Army, 1997), pp.129–80.Google Scholar
  53. 50.
    J. S. Ketchum, and R R. Sidell, ‘Incapacitating Agents’, note 32.Google Scholar
  54. 51.
    E. J. Nestler et al., Molecular Neuropharmacology: a Foundation for Clinical Neuroscience (New York: McGraw-Hill Medical, 2001).Google Scholar
  55. 52.
    C. C. Felder et al., ‘Therapeutic opportunities for muscarinic receptors in the central nervous system’, J. Medical Chemistry, 43 (23), 2000, 4333–53.CrossRefGoogle Scholar
  56. 53.
    N. J. M. Birdsall, ‘Muscarinic acetylcholine receptors’, The IUPHAR Receptor Compendium (London: IUPHAR Media, 1998), pp.37–45.Google Scholar
  57. 54.
    R P. Bymaster et al., ‘Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic choliergic system’, Neurochem. Res., 28 (3–4), 2003, 437–42.CrossRefGoogle Scholar
  58. 55.
    W. Zhang et al., ‘Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice’, J. Neuroscience, 22 (5), 2002, 1709–17.Google Scholar
  59. 56.
    J. E. Lachowicz et al., ‘Discovery of SCH211803, a high affinity, selective M2 receptor antagonist and a novel approach to treatment of Alzheimer’s Disease’, Soc. Neurosci. Abstr., 27, 2001, 679.Google Scholar
  60. 57.
    Y. Wang, et al., ‘Improving the oral efficacy of CNS drug candidates: Discovery of highly orally efficacious piperidinyl piperidine M2 muscarinic receptor antagonists’, J. Medical Chemistry, 45 (25), 2002, 5415–18.CrossRefGoogle Scholar
  61. 58.
    A. Lonsgstaff, Instant Notes: Neuroscience. 2nd edition (New York: Taylor and Francis, 2000), especially section M4, ‘Brain Biological Clocks’.Google Scholar
  62. 59.
    H. Okamura, ‘Integration of mammalian circadian clock signals: from molecule to behaviour’, Journal of Endocrinology, 177, 2003, 3–6.CrossRefGoogle Scholar
  63. 60.
    H. D. Piggins and D.J. Cutler, ‘The roles of vasocactive intestinal polypeptide in the mammalian circadian clock’, Journal of Endocrinology, 177, 2003, 7–15.CrossRefGoogle Scholar
  64. 61.
    A. Longstaff, ‘Sleep’, Section 04, in note 58.Google Scholar
  65. 62.
    W. McDowell Anderson, ‘Top ten list in sleep’, Chest, 122 (4), 2002, 1457–60.CrossRefGoogle Scholar
  66. 63.
    S. Taheri et al., ‘The role of hypocretins (orexins) in sleep regulation and narcolepsy’, Annu. Rev. Neurosci., 25, 2002, 283–313.CrossRefGoogle Scholar
  67. 64.
    L. de Lecea, et al., ‘The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity’, Proc. Nat. Acad. Sci., 95, 1998, 322–7.CrossRefGoogle Scholar
  68. 65.
    T. Sakurai et al., ‘Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behaviour’, Cell, 92, 1998, 573–85.CrossRefGoogle Scholar
  69. 66.
    P. Bourgin et al., ‘Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons’, J. Neurosci., 20, 2000, 7760–7.Google Scholar
  70. 67.

Copyright information

© Alexander Kelle, Kathryn Nixdorff and Malcolm Dando 2006

Authors and Affiliations

  • Alexander Kelle
    • 1
  • Kathryn Nixdorff
    • 2
  • Malcolm Dando
    • 3
  1. 1.School of Politics, International Studies and PhilosophyQueen’s University BelfastUK
  2. 2.Darmstadt University of TechnologyGermany
  3. 3.Department of Peace StudiesUniversity of BradfordBradfordUK

Personalised recommendations